 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...200201202203204205206207208209210...235236» |
- ||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
New P1/2 trial, Combination therapy: LUD2015-005: Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer (clinicaltrials.gov) - Apr 12, 2016
P1/2, N=75, Not yet recruiting, Sponsor: Ludwig Institute for Cancer Research
- leucovorin calcium / Generic mfg.
Trial primary completion date: Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study (clinicaltrials.gov) - Apr 9, 2016
P=N/A, N=12, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2016 --> Dec 2017
- | Biomarker, Enrollment open, Surgery: TRIGGER: Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial (clinicaltrials.gov) - Apr 8, 2016
P2/3, N=90, Recruiting, Sponsor: Royal Marsden NHS Foundation Trust
Trial primary completion date: Dec 2016 --> Dec 2017 Not yet recruiting --> Recruiting
- || Inlyta (axitinib) / Pfizer
Trial primary completion date, Metastases: A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Apr 7, 2016
P2, N=70, Completed, Sponsor: SCRI Development Innovations, LLC
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2015 --> Jul 2015
- || Avastin (bevacizumab) / Roche, onartuzumab (RG3638) / Roche
Trial primary completion date, Metastases: FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 7, 2016
P2, N=194, Completed, Sponsor: Genentech, Inc.
Trial primary completion date: Apr 2015 --> Jul 2015 Trial primary completion date: Oct 2014 --> Mar 2013
- Zaltrap (ziv-aflibercept IV) / Sanofi
Trial primary completion date: 5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer (clinicaltrials.gov) - Apr 7, 2016
P2, N=39, Completed, Sponsor: SCRI Development Innovations, LLC
Trial primary completion date: Oct 2014 --> Mar 2013 Trial primary completion date: Jun 2015 --> Sep 2015
- || Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: GP28328: A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Apr 7, 2016
P1, N=225, Recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Jun 2015 --> Sep 2015 Trial primary completion date: Feb 2016 --> Sep 2017
- ||| vanucizumab (RG7221) / Roche, Avastin (bevacizumab) / Roche
Enrollment change, Metastases: McCAVE: A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 7, 2016
P2, N=198, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Feb 2016 --> Sep 2017 N=150 --> 198
- | Herceptin (trastuzumab) / Roche, Opdivo (nivolumab) / BMS
Enrollment open, HEOR: RENAISSANCE: Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (clinicaltrials.gov) - Apr 7, 2016
P3, N=271, Recruiting, Sponsor: Krankenhaus Nordwest
N=150 --> 198 Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche
Enrollment open, Trial initiation date: CARCINOSIS: Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer (clinicaltrials.gov) - Apr 6, 2016
P2, N=30, Recruiting, Sponsor: Medical University of Vienna
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> Mar 2016
- | Keytruda (pembrolizumab) / Merck (MSD)
New P1/2 trial, PD(L)-1 Biomarker, Surgery, Metastases: Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Apr 6, 2016
P1/2, N=68, Not yet recruiting, Sponsor: Mayo Clinic
- leucovorin calcium / Generic mfg.
Trial primary completion date: A Folinic Acid Intervention for Autism Spectrum Disorders (clinicaltrials.gov) - Apr 1, 2016
P2, N=99, Terminated, Sponsor: University of Arkansas
Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> Mar 2016 Trial primary completion date: Jun 2015 --> Nov 2015
- Erbitux (cetuximab) / Eli Lilly
Enrollment open, Trial initiation date, Combination therapy, Metastases: Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer (clinicaltrials.gov) - Apr 1, 2016
P1, N=45, Recruiting, Sponsor: University of Chicago
Trial primary completion date: Jun 2015 --> Nov 2015 Not yet recruiting --> Recruiting | Initiation date: Nov 2015 --> Jun 2015
- ||| BNC-101 / Carina Biotech
New P1 trial, Metastases: A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer. (clinicaltrials.gov) - Apr 1, 2016
P1, N=54, Not yet recruiting, Sponsor: Bionomics Limited
- ||||| Jakafi (ruxolitinib) / Incyte
New P2 trial: AALL1521: A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 31, 2016
P2, N=170, Not yet recruiting, Sponsor: Incyte Corporation
- ||||||| Trial completion, Combination therapy, Metastases: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 30, 2016
P3, N=627, Completed, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting | Initiation date: Nov 2015 --> Jun 2015 Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment closed: ATOM: Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (clinicaltrials.gov) - Mar 29, 2016
P2, N=120, Active, not recruiting, Sponsor: EPS Corporation
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Biomarker, Enrollment closed: ATOM ES: Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (clinicaltrials.gov) - Mar 29, 2016
P=N/A, N=100, Active, not recruiting, Sponsor: EPS Corporation
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Oncaspar liquid (pegaspargase) / Servier
Clinical: Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 28, 2016
P2/3, N=63, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Phase classification: P3 --> P2/3
- || napabucasin (BBI608) / Sumitomo Pharma
Enrollment change, Trial primary completion date, Combination therapy, Metastases: A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer (clinicaltrials.gov) - Mar 25, 2016
P1, N=250, Recruiting, Sponsor: Boston Biomedical, Inc
Phase classification: P3 --> P2/3 N=64 --> 250 | Trial primary completion date: Jun 2016 --> Jun 2018
- ||||| New P1/2 trial, Monotherapy, Metastases: Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) (clinicaltrials.gov) - Mar 25, 2016
P1/2, N=70, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | futuximab/modotuximab (S95026) / Servier
Enrollment open, Combination therapy, Metastases: Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Mar 24, 2016
P1/2, N=50, Recruiting, Sponsor: Symphogen A/S
N=64 --> 250 | Trial primary completion date: Jun 2016 --> Jun 2018 Not yet recruiting --> Recruiting
- |||| Tepylute (thiotepa ready to dilute) / Shorla Oncology, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial primary completion date: COG-ACNS0334: Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma (clinicaltrials.gov) - Mar 23, 2016
P3, N=96, Active, not recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2018 --> Mar 2016
- Erbitux (cetuximab) / Eli Lilly
Trial completion, Metastases: Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 23, 2016
P2, N=169, Completed, Sponsor: Cheryl Pugh
Trial primary completion date: Sep 2018 --> Mar 2016 Active, not recruiting --> Completed
- New P2 trial: Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Mar 23, 2016
P2, N=50, Enrolling by invitation, Sponsor: Nagoya University
- Trial completion: Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer (clinicaltrials.gov) - Mar 22, 2016
P1, N=13, Completed, Sponsor: Emory University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
New P1 trial, Combination therapy: A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors (clinicaltrials.gov) - Mar 22, 2016
P1, N=60, Not yet recruiting, Sponsor: Hoffmann-La Roche
- Trial primary completion date: Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer (clinicaltrials.gov) - Mar 21, 2016
P2, N=65, Recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Trial primary completion date: Feb 2017 --> Feb 2018
- ||| Vectibix (panitumumab) / Amgen
Enrollment change: PanaMa: Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 21, 2016
P2, N=380, Recruiting, Sponsor: AIO-Studien-gGmbH
Trial primary completion date: Feb 2017 --> Feb 2018 N=280 --> 380
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial completion: Phase II Trial Evaluating OS With Therasphere (clinicaltrials.gov) - Mar 18, 2016
P2, N=9, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
N=280 --> 380 Active, not recruiting --> Completed
- | Enrollment closed, Metastases: Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 18, 2016
P2/3, N=134, Active, not recruiting, Sponsor: Guangxi Medical University
Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting
- | Enrollment closed, Metastases: Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 18, 2016
P2/3, N=90, Active, not recruiting, Sponsor: Guangxi Medical University
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting
- sapitinib (AZD8931) / AstraZeneca
Trial primary completion date, Combination therapy: PANTHER: Phase I/II Trial of Antagonism of HER in GI Cancer (clinicaltrials.gov) - Mar 16, 2016
P1/2, N=24, Recruiting, Sponsor: University College, London
Not yet recruiting --> Active, not recruiting Trial primary completion date: Feb 2016 --> Jun 2016
- Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
Trial primary completion date: Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab (clinicaltrials.gov) - Mar 16, 2016
P2, N=35, Recruiting, Sponsor: Christina Wu
Trial primary completion date: Feb 2016 --> Jun 2016 Trial primary completion date: Dec 2015 --> Dec 2017
- Avastin (bevacizumab) / Roche
Biomarker: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Mar 16, 2016
P3, N=3610, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2015 --> Dec 2017 Trial primary completion date: Mar 2016 --> Jul 2016
- || Biomarker, New P2/3 trial, Surgery: TRIGGER: Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial (clinicaltrials.gov) - Mar 10, 2016
P2/3, N=90, Not yet recruiting, Sponsor: Royal Marsden NHS Foundation Trust
- | New P2 trial, Adverse events, Combination therapy, Metastases: Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 10, 2016
P2, N=70, Not yet recruiting, Sponsor: Vejle Hospital
- Enrollment change, Trial withdrawal: Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers (clinicaltrials.gov) - Mar 8, 2016
P2, N=0, Withdrawn, Sponsor: Washington University School of Medicine
Trial primary completion date: Mar 2016 --> Jul 2016 N=50 --> 0 | Recruiting --> Withdrawn
- ||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment closed, Trial primary completion date, Metastases: Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer (clinicaltrials.gov) - Mar 7, 2016
P2, N=228, Active, not recruiting, Sponsor: Yonsei University
N=50 --> 0 | Recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Aug 2016
- Farydak (panobinostat) / Secura Bio
Enrollment open, Combination therapy: Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Mar 6, 2016
P1/2, N=36, Recruiting, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Aug 2016 Not yet recruiting --> Recruiting
- || Vectibix (panitumumab) / Amgen
Trial primary completion date: Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov) - Mar 5, 2016
P2, N=78, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2016 --> Mar 2017
- NN1213 / Novo Nordisk
Trial primary completion date, Surgery, Metastases: Radiation Therapy and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Patients With Rectal Cancer (clinicaltrials.gov) - Mar 5, 2016
P2, N=23, Active, not recruiting, Sponsor: Fox Chase Cancer Center
Trial primary completion date: Mar 2016 --> Mar 2017 Trial primary completion date: Jul 2014 --> Jul 2016
- Avastin (bevacizumab) / Roche
Enrollment closed, Enrollment change, Trial primary completion date, Surgery, Metastases: Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer (clinicaltrials.gov) - Mar 5, 2016
P2, N=20, Active, not recruiting, Sponsor: Fox Chase Cancer Center
Trial primary completion date: Jul 2014 --> Jul 2016 Recruiting --> Active, not recruiting | N=39 --> 20 | Trial primary completion date: Dec 2015 --> Oct 2014
- Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment closed, Combination therapy, Metastases: MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 4, 2016
P1, N=34, Active, not recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting | N=39 --> 20 | Trial primary completion date: Dec 2015 --> Oct 2014 Recruiting --> Active, not recruiting
- || Vectibix (panitumumab) / Amgen
Trial primary completion date, HEOR: SILQ: ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line (clinicaltrials.gov) - Mar 2, 2016
P=N/A, N=300, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2017 --> Apr 2018
- ||||||| Vectibix (panitumumab) / Amgen
Trial completion: PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study (clinicaltrials.gov) - Feb 27, 2016
P3, N=1053, Completed, Sponsor: Amgen
Trial primary completion date: Mar 2017 --> Apr 2018 Recruiting --> Completed
- | Avonex (recombinant IFN-?-1a) / Biogen
Trial completion, Combination therapy: Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis (clinicaltrials.gov) - Feb 27, 2016
P4, N=16, Completed, Sponsor: MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
Recruiting --> Completed No longer recruiting --> Completed
- Avastin (bevacizumab) / Roche
Enrollment change: Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer (clinicaltrials.gov) - Feb 27, 2016
P3, N=355, Terminated, Sponsor: ECOG-ACRIN Cancer Research Group
No longer recruiting --> Completed N=2100 --> 355
- Rituxan (rituximab) / Roche, Matulane (procarbazine hydrochloride) / Leadiant Biosci
Trial completion, Trial primary completion date: Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma (clinicaltrials.gov) - Feb 27, 2016
P=N/A, N=52, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
N=2100 --> 355 Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Feb 2016
- LY2090314 / Eli Lilly
Enrollment change, Trial termination, Trial primary completion date, Metastases, Biopsy: A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Feb 26, 2016
P1/2, N=13, Terminated, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Feb 2016 N=45 --> 13 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Jun 2015; Study has been terminated due to slow enrollment.